The purchase price comprises an initial cash payment of DKK 135 million at closing for 100% of the company’s shares, with a potential additional payment of up to DKK 140 million contingent upon the gross profit growth in 2025 and 2026.

Currently, XGX’s has seven products on the market, primarily in the Nordics. The pipeline consists of 20 niche products in either late-stage development or registration phase. Expected product launches for this pipeline will be during the coming years. XGX’s net sales during the last 12 months amounted to 51m DKK, a growth of 91% compared to the same period previous year. The EBITDA margin for the last 12 months was 35%.

”With the addition of XGX, we can take the next step with Unimedic. We add scale in Unimedic’s home markets and a pipeline that will offer strong growth opportunities. I’m especially impressed by both team’s expertise and entrepreneurial mindset, and I look forward to what we can achieve together,” says Anders Larnholt, Head of Business Area Specialty Pharma and Chairman of Unimedic comments the acquisition: 

If approved, the acquisition is expected to close during the third quarter of 2025.